The latest approval for Bristol-Myers Squibb Co.’s PD-1 inhibitor Opdivo (nivolumab) puts the drug back on equal footing with Merck & Co. Inc.’s Keytruda (pembrolizumab) in melanoma and increases pressure on the marketed BRAF inhibitors.
Opdivo's approval, as monotherapy and in combination with the company’s own CTLA-4 inhibitor Yervoy (ipilimumab), in patients with unresectable or...